45 CFR § 180 compliance
B · 85
This hospital published most of what § 180 requires.
●Machine-readable file published
○Gross / standard charges
●Discounted cash price
●Payer-specific negotiated rates
●Min / max negotiated charges
●Free, public, no login required
Procedures listed
13,184
Insurances with rates
15
CPT / HCPCS codes
11,703
Source MRF
Most expensive procedures (gross)
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| J0225 | VUTRISIRAN 25 MG/0.5 ML SUBCUTANEOUS SYRINGE | $744,578 | $214,618 | $409,518 | $558,434 | 4 |
| J0225 | VUTRISIRAN 25 MG/0.5 ML SUBCUTANEOUS SYRINGE | $744,578 | $214,618 | $372,289 | $558,434 | 3 |
| J1303 | RAVULIZUMAB-CWVZ 10 MG/ML INTRAVENOUS SOLUTION | $399,514 | $115,156 | $219,733 | $299,636 | 4 |
| J1303 | RAVULIZUMAB-CWVZ 10 MG/ML INTRAVENOUS SOLUTION | $399,514 | $115,156 | $221 | $299,636 | 29 |
| 90378 | PALIVIZUMAB 100 MG/ML INTRAMUSCULAR SOLUTION | $293,083 | $84,478 | $161,196 | $219,812 | 4 |
| 90378 | PALIVIZUMAB 100 MG/ML INTRAMUSCULAR SOLUTION | $293,083 | $84,478 | $340 | $219,812 | 30 |
| J0285 | AMPHOTERICIN B 0.1 MG/ML IV SYRINGE (NEONATE) | $290,074 | $83,611 | $159,541 | $217,556 | 4 |
| J0285 | AMPHOTERICIN B 0.1 MG/ML IV SYRINGE (NEONATE) | $290,074 | $83,611 | $145,037 | $217,556 | 3 |
| C1877 | THRAFLX HBRD ANTFLO 30X40X150A THA3040X150A | $248,448 | $71,613 | $136,646 | $186,336 | 3 |
| C1877 | THRAFLX HBRD ANTFLO 30X40X150A THA3040X150A | $248,448 | $71,613 | $124,224 | $186,336 | 3 |
| C1882 | ACTICOR 7 HF-T 429523 | $187,374 | $54,009 | $131,162 | $140,531 | 3 |
| C1882 | ACTICOR 7 HF-T 429523 | $187,374 | $54,009 | $93,687 | $140,531 | 3 |
| J2020 | LINEZOLID 2 MG/ML IV SYRINGE (NEONATE) | $176,905 | $50,991 | $97,298 | $132,679 | 4 |
| J2020 | LINEZOLID 2 MG/ML IV SYRINGE (NEONATE) | $176,905 | $50,991 | $146 | $132,679 | 4 |
| C1605 | PACER SYS AVEIR DUAL CHAMBER DR-SYSTEM-AVEIR | $170,364 | $49,106 | $119,255 | $127,773 | 3 |
| C1605 | PACER SYS AVEIR DUAL CHAMBER DR-SYSTEM-AVEIR | $170,364 | $49,106 | $85,182 | $127,773 | 3 |
| C1824 | OPTIMIZER SMART IPG 10-B411-3-XX | $163,266 | $47,060 | $89,796 | $122,449 | 3 |
| C1824 | OPTIMIZER SMART IPG 10-B411-3-XX | $163,266 | $47,060 | $81,633 | $122,449 | 3 |
| J1747 | SPESOLIMAB-SBZO 60 MG/ML INTRAVENOUS SOLUTION | $162,690 | $46,894 | $89,480 | $122,018 | 4 |
| J1747 | SPESOLIMAB-SBZO 60 MG/ML INTRAVENOUS SOLUTION | $162,690 | $46,894 | $81,345 | $122,018 | 3 |
| C1820 | KT IMP VERCISE GEVIA GENRTR M365DB1200S0 | $156,167 | $45,014 | $85,892 | $117,125 | 3 |
| C1820 | KT IMP VERCISE GEVIA GENRTR M365DB1200S0 | $156,167 | $45,014 | $78,084 | $117,125 | 3 |
| C1826 | NEUROSTIMULATOR RECHRG 977119 | $156,167 | $45,014 | $85,892 | $117,125 | 3 |
| C1826 | NEUROSTIMULATOR RECHRG 977119 | $156,167 | $45,014 | $78,084 | $117,125 | 3 |
| J9266 | PEGASPARGASE 750 UNIT/ML INJECTION SOLUTION | $155,647 | $44,864 | $85,606 | $116,735 | 4 |
| J9266 | PEGASPARGASE 750 UNIT/ML INJECTION SOLUTION | $155,647 | $44,864 | $11,049 | $135,004 | 30 |
| C1767 | DRG IPG PROCLAIM W/CONTROLLER 3664CTRLSYSXX | $152,937 | $44,083 | $84,115 | $114,703 | 3 |
| C1767 | DRG IPG PROCLAIM W/CONTROLLER 3664CTRLSYSXX | $152,937 | $44,083 | $76,469 | $114,703 | 3 |
| C2624 | SYS DEL PA SENS CARDIOMEMS CM2000 | $149,069 | $42,968 | $81,988 | $111,801 | 3 |
| C2624 | SYS DEL PA SENS CARDIOMEMS CM2000 | $149,069 | $42,968 | $74,534 | $111,801 | 3 |
| J9228 | IPILIMUMAB 200 MG/40 ML (5 MG/ML) INTRAVENOUS SOLUTION | $146,973 | $42,364 | $80,835 | $110,230 | 4 |
| J9228 | IPILIMUMAB 200 MG/40 ML (5 MG/ML) INTRAVENOUS SOLUTION | $146,973 | $42,364 | $172 | $110,230 | 30 |
| J9359 | LONCASTUXIMAB TESIRINE-LPYL 10 MG INTRAVENOUS SOLUTION | $146,606 | $42,258 | $80,633 | $109,955 | 4 |
| J9359 | LONCASTUXIMAB TESIRINE-LPYL 10 MG INTRAVENOUS SOLUTION | $146,606 | $42,258 | $73,303 | $109,955 | 3 |
| J0222 | PATISIRAN (LIPID COMPLEX) 2 MG/ML INTRAVENOUS SOLUTION | $141,054 | $40,658 | $77,580 | $105,791 | 4 |
| J0222 | PATISIRAN (LIPID COMPLEX) 2 MG/ML INTRAVENOUS SOLUTION | $141,054 | $40,658 | $98.83 | $105,791 | 29 |
| C2616 | THERASPHERE Y-90 1-20GBQ Y90THERA | $125,998 | $36,318 | $69,299 | $94,499 | 3 |
| C2616 | THERASPHERE Y-90 1-20GBQ Y90THERA | $125,998 | $36,318 | $19,818 | $94,499 | 30 |
| J9229 | INOTUZUMAB OZOGAMICIN 0.9 MG(0.25 MG/ML INITIAL CONCENTRATION) IV SOLN | $124,046 | $35,755 | $68,225 | $93,035 | 4 |
| J9229 | INOTUZUMAB OZOGAMICIN 0.9 MG(0.25 MG/ML INITIAL CONCENTRATION) IV SOLN | $124,046 | $35,755 | $2,580 | $93,035 | 29 |
| C1787 | KT PULSE GEN 16 WAVEWRITER ALP M365SC12160 | $115,706 | $33,351 | $63,638 | $86,779 | 3 |
| C1787 | KT PULSE GEN 16 WAVEWRITER ALP M365SC12160 | $115,706 | $33,351 | $57,853 | $86,779 | 3 |
| 77371 | HC SRS CMPL MS GAMMA KNIFE TMT | $114,636 | $33,043 | $82,538 | $85,977 | 2 |
| 77371 | HC SRS CMPL MS GAMMA KNIFE TMT | $114,636 | $33,043 | $8,665 | $85,977 | 30 |
| J9350 | MOSUNETUZUMAB-AXGB 1 MG/ML INTRAVENOUS SOLUTION | $114,570 | $33,024 | $63,014 | $85,928 | 4 |
| J9350 | MOSUNETUZUMAB-AXGB 1 MG/ML INTRAVENOUS SOLUTION | $114,570 | $33,024 | $57,285 | $85,928 | 3 |
| C1822 | IPG W/KIT NIPG1500 | $113,576 | $32,737 | $62,467 | $85,182 | 3 |
| C1822 | IPG W/KIT NIPG1500 | $113,576 | $32,737 | $56,788 | $85,182 | 3 |
| L8614 | IMP COCHLEAR MODEL CI624 O P1431676 | $111,154 | $32,039 | $61,135 | $83,365 | 3 |
| L8614 | IMP COCHLEAR MODEL CI624 O P1431676 | $111,154 | $32,039 | $55,577 | $83,365 | 3 |
Showing top 50 of 13,184 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.